|
SCIENTIFIC ADVISORY BOARD
Neil Granger, Ph.D. Dr. Granger is the Professor and Head of the Department of Molecular and Cellular Physiology, and Associate Dean for Research, Louisiana State University Health Science Center in Shreveport. Dr. Granger earned a PhD degree in Physiology and Biophysics from the University of Mississippi Medical Center in 1977. His areas of research expertise include the microcirculation, oxygen radical biology, and ischemia-reperfusion injury. Dr. Granger has served on the editorial board of 12 scientific journals, and as associate editor for the American Journal of Physiology, and Pathophysiology. He is presently Editor-in-Chief of the journal Microcirculation. His accomplishments as a researcher have been recognized through awards presented by several scientific organizations, including the American Physiological Society (Bowditch Award & Distinguished Research Award in GI Physiology), Microcirculatory Society (Landis Award), and Society for Critical Care Medicine (Laerdal Award).
Anil Gulati, M.D. Professor Gulati
is a professor at the University of Illinois, Chicago, and has
served as the Director of the Pharmacokinetic and Pharmacodynamic
Laboratory.
Dr
Anil Gulati has six inventions to his credit and has published more
than 175 papers in peer reviewed journals and edited two books. Dr
Gulati is also a member of many national and International
scientific societies and has won a number of national and
international awards. He has rich experience as head of a large
number of research projects and has collaborations for research with
some of the leading pharmaceutical companies of the world like
Bristol-Myers Squibb, Baxter Healthcare and a number of research
institutes all over the world. He also serves on the Board of
Directors of
Chandigarh-based
Venus Remedies Ltd. Dr. Gulati has extensive experience in the
evaluation of blood substitutes and is responsible for the
contracted pre-clinical efficacy testing of HemoZyme®.
Lyn Yaffe, MD Former Director of Medical
Research and Development at the U.S. Navy, Dr. Yaffe currently
coordinates the execution of the IITRI/SynZyme Teaming Agreement. At
IITRI, Dr. Yaffe actively promotes the corporate and government
funding of the HemoZyme development program.
Jay L. Zweier, Ph.D. MD, received his MD
in 1980 from the University of Maryland School of Medicine. He
completed his residency in internal medicine and a fellowship in
cardiology before joining the faculty of Johns Hopkins University
School of Medicine where he was appointed as Chief of Cardiology
Research in 2000. In addition to serving as Professor of Medicine
in the Cardiology and Pulmonary Divisions, Dr. Zweier also held
appointments as Professor of Radiology and Environmental Health
Sciences in the Schools of Medicine and Public Health, respectively.
In 2002, Dr. Zweier joined Ohio State University College of Medicine
as the Director of the Davis Heart & Lung Research Institute and as
the John H. and Mildred C. Lumley Chair in Medicine. He has been a
member of six international advisory boards for magnetic resonance
centers and actively reviews for or serves on the editorial boards
of numerous journals. He has been the recipient of more than 75
endowed lectureships and awards in the US and abroad. Dr. Zweier
has published over 200 peer reviewed manuscripts in the fields of
cardiovascular research, free radical biology and magnetic
resonance. As principal investigator, program leader, project leader
and investigator, Dr. Zweier has been awarded over $60 million in
support from the National Institutes of Health and other funding
agencies.
Pak H. Chan, Ph.D., is a tenured
Professor of Neurosurgery, Professor of Neurology and Neurological
Sciences, a faculty member of the Program in Neurosciences and the
Stanford Brain Research Institute, and Vice Chairman and Director of
Research of the Department of Neurosurgery, Stanford University
School of Medicine. He formerly was a Professor of Neurosurgery and
Neurology and Director of the CNS Injury and Research Center at the
University of California, San Francisco. He is currently President
of the National Neurotrauma Society and was the Chairman of the
prestigious 22nd Princeton Conference on Cerebrovascular Disease.
Dr. Chan has served on United States government public advisory
committees, including the NIH Neurology Study Section, NIH NINDS
NSDA Study Section, and numerous review committees. He is currently
a recipient of the prestigious NIH Jacob Javits Neuroscience
Investigator Award. Dr. Chan's research interests are in molecular
and cellular mechanisms of ischemic cell death and neuroprotection
against CNS injury, including stroke and head trauma. He has nine
active NIH grants that total more than $2.5 million a year. Dr. Chan
has published more than 200 peer-reviewed articles in prestigious
journals. He received his B.S. degree from the Chinese University of
Hong Kong and his Ph.D. from the University of California, Los
Angeles.
Michael E. Mosley, Ph.D., an Associate Professor of Radiology
at Stanford University, is on the editorial boards of prestigious
journals such as Journal Magnetic Resonance Imaging,
MagneticResonance Medicine, Neuroimage, and the Journal of Cerebral
Blood Flow and Metabolism. He has served on the faculty of the
University of California, San Francisco, and garnered several
prizes, including first prize at the XIII Symposium,
Neuroradiologicum in Stockholm and the 2001 Gold Medal from the
ISMRM. Dr. Moseley, who completed post-doctoral work at Israel's
Weizmann Institute of Science and UCSF, received his B.S. at North
Carolina State University and his Ph.D. at Sweden's Uppsala
University.
Gary Rosenberg, M.D. is a Professor and Chairman of
Neurology. He is Chief of Neurology at the University of New Mexico
Hospital and Director of the Residency Training Program. Dr.
Rosenberg’s research focuses on the role of the blood-brain barrier
in brain edema after stroke has been funded by the March of Dimes,
Veteran's Administration, American Heart Association, and the
National Institutes of Health. Dr. Rosenberg received his MD from
the Albert Einstein College of Medicine.
Jerry L MuCullough, Ph.D., is the Chairman of the Department
of Dermatology at the University of California, Irvine where he has
been Director of Dermatology Research and Immunofluorescence
Laboratories since 1979. Dr. McCullough is also a pioneer in the
field of Dermatopharmacology. His major focus of research has been
on studies relating to the basic pathophysiology of psoriasis and
other hyperproliferative skin diseases. His work on in vitro and in
vivo models has resulted in the development of topical drug
formulations for psoriasis, including methotrexate and
hematoporphyrin derivative. The many patents that the University of
California has filed on his behalf, each involving new therapies for
skin disorders, exemplify the relevance of his research
productivity. Dr. McCullough received his Ph.D. in pharmacology at
Yale University.
|
